A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER

The REVEAL-BTC Study will analyze 5 biomarkes in samples of participants who in the past 15 year have been diagnosed with any stage of biliary tract cancer. The expression levels of the biomarkers will be correlated with clinical outcomes in the participants, which will lead to better patient stratification that will help guide the use of targeted therapies in the future.

NCT Number	NCT07515950
Lead Sponsor	MedSIR Collaborators: AstraZeneca
Conditions	Biliary Tract Cancer (BTC)
Enrollment	244 participants
Start Date	2026-07
Primary Completion	2027-05 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-07